These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients. Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488 [TBL] [Abstract][Full Text] [Related]
5. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer. Boehm K; Schiffmann J; Tian Z; Lesmana H; Larcher A; Mandel P; Karakiewicz PI; Graefen M; Schwarz R; Krüll A; Tilki D Urol Oncol; 2016 Mar; 34(3):119.e11-8. PubMed ID: 26602027 [TBL] [Abstract][Full Text] [Related]
6. Aetiology and management of earlier vs later biochemical recurrence after retropubic radical prostatectomy. Llukani E; Lepor H BJU Int; 2017 Oct; 120(4):505-510. PubMed ID: 28220652 [TBL] [Abstract][Full Text] [Related]
7. Short (≤ 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy. Shikanov S; Marchetti P; Desai V; Razmaria A; Antic T; Al-Ahmadie H; Zagaja G; Eggener S; Brendler C; Shalhav A BJU Int; 2013 Apr; 111(4):559-63. PubMed ID: 22759270 [TBL] [Abstract][Full Text] [Related]
8. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495 [TBL] [Abstract][Full Text] [Related]
9. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342 [TBL] [Abstract][Full Text] [Related]
10. Risk stratification of patients with extraprostatic extension and negative lymph nodes at radical prostatectomy: identifying optimal candidates for adjuvant therapy. Eisenberg MS; Karnes RJ; Kaushik D; Rangel L; Bergstralh EJ; Boorjian SA J Urol; 2013 Nov; 190(5):1735-41. PubMed ID: 23727312 [TBL] [Abstract][Full Text] [Related]
11. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies. Briganti A; Joniau S; Gandaglia G; Cozzarini C; Sun M; Tombal B; Haustermans K; Hinkelbein W; Shariat SF; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):960-7. PubMed ID: 24351411 [TBL] [Abstract][Full Text] [Related]
12. Radical prostatectomy and positive surgical margins: relationship with prostate cancer outcome. De La Roca RL; Da Cunha IW; Bezerra SM; Da Fonseca FP Int Braz J Urol; 2014; 40(3):306-15. PubMed ID: 25010296 [TBL] [Abstract][Full Text] [Related]
13. Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era. Isbarn H; Wanner M; Salomon G; Steuber T; Schlomm T; Köllermann J; Sauter G; Haese A; Heinzer H; Huland H; Graefen M BJU Int; 2010 Jul; 106(1):37-43. PubMed ID: 20002667 [TBL] [Abstract][Full Text] [Related]
14. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study. Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833 [TBL] [Abstract][Full Text] [Related]
15. Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy. Viers BR; Sukov WR; Gettman MT; Rangel LJ; Bergstralh EJ; Frank I; Tollefson MK; Thompson RH; Boorjian SA; Karnes RJ Eur Urol; 2014 Dec; 66(6):1116-24. PubMed ID: 25052213 [TBL] [Abstract][Full Text] [Related]
16. The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients. Mauermann J; Fradet V; Lacombe L; Dujardin T; Tiguert R; Tetu B; Fradet Y Eur Urol; 2013 Jul; 64(1):19-25. PubMed ID: 22901983 [TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184 [TBL] [Abstract][Full Text] [Related]
18. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. Swindle P; Eastham JA; Ohori M; Kattan MW; Wheeler T; Maru N; Slawin K; Scardino PT J Urol; 2005 Sep; 174(3):903-7. PubMed ID: 16093984 [TBL] [Abstract][Full Text] [Related]
19. Long-term cancer control after radical prostatectomy and bilateral pelvic lymph node dissection for pT3bN0M0 prostate cancer in the prostate-specific antigen era. Fairey AS; Daneshmand S; Skinner EC; Schuckman A; Cai J; Lieskovsky G Urol Oncol; 2014 Feb; 32(2):85-91. PubMed ID: 24183191 [TBL] [Abstract][Full Text] [Related]
20. Long-term biochemical recurrence rates after robot-assisted radical prostatectomy: analysis of a single-center series of patients with a minimum follow-up of 5 years. Suardi N; Ficarra V; Willemsen P; De Wil P; Gallina A; De Naeyer G; Schatteman P; Montorsi F; Carpentier P; Mottrie A Urology; 2012 Jan; 79(1):133-8. PubMed ID: 22088567 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]